Recent Updates
Recently added Catalysts
GH Positive Sentiment

Guardant Health Applauds New Law Ensuring Access to Colorectal Cancer Screening Innovations with No Cost-Sharing for Pennsylvanians

Thursday, October 29, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Guardant Health praised Pennsylvania's new law (HB 1123) that aligns insurance coverage for colorectal cancer screenings with the latest ACS and NCCN guidelines. This legislation eliminates cost-sharing for around 2 million residents eligible for screening. The company views this as a significant advancement in cancer care access.

Market Sentiment Analysis

POSITIVE FACTORS

  • New law ensures no cost-sharing for screenings.
  • Aligns insurance coverage with latest guidelines.
  • Benefits approximately 2 million eligible residents.

Full Press Release Details

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, applauded the enactment of a new law (HB 1123) in Pennsylvania aligning insurance coverage for colorectal cancer screening to reflect the latest American Cancer Society (ACS) and National Comprehensive Cancer Center (NCCN) guidelines, ensuring no cost-sharing for about 2 million Pennsylvanians of screening-eligible age.1The landmark legislation marks a historic moment for states proactiv

Frequently Asked Questions

What is the new law in Pennsylvania about?

The law aligns insurance coverage for colorectal cancer screenings with updated guidelines.

Who benefits from this new law?

Approximately 2 million Pennsylvanians of screening-eligible age benefit.

Is there any cost-sharing for screenings?

No, the law ensures there is no cost-sharing for eligible screenings.

What guidelines does the law reflect?

It reflects the latest American Cancer Society and NCCN guidelines.

ShareAdd on Google
Tags: GH Guardant Health colorectal cancer screening Pennsylvania insurance coverage
Last updated: Oct 29, 2026

Biotech snapshot

Cash runway
$1053M liquidity · $19M/mo burn
~52 mo
Minimal dilution risk